AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis

Recruitingn/aAges 18 Years - 80 YearsAllBeijing Anzhen Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Age โ‰ฅ18 years and โ‰ค80 years. 2. Definite diagnosis of STEMI according to ESC/ACC guidelines: * Chest pain lasting \>30 minutes, and * ST-segment elevation in at least two contiguous leads: โ‰ฅ0.2 mV in leads V2-V3 (โ‰ฅ0.2 mV for men, โ‰ฅ0.15 mV for women) or โ‰ฅ0.1 mV in other leads, or new-onset left bundle branch block. 3. Reperfusion therapy: Symptom onset to first medical contact โ‰ค12 hours, and successful primary PCI (culprit vessel opened, post-procedure TIMI flow grade 3). 4. First STEMI (no prior history of myocardial infarction). 5. Left ventricular ejection fraction (by echocardiography within 24-48 hours after admission) โ‰ฅ35%. 6. Informed consent: Signed informed consent obtained, with willingness to undergo serial blood sampling and echocardiographic follow-up. Exclusion Criteria: 1. Non-atherosclerotic MI: coronary embolism, spasm, aortic dissection, myocarditis, Takotsubo. 2. Severe comorbidities: * Prior HF (NYHA โ‰ฅII); * Severe CKD (eGFR \<30 mL/min/1.73mยฒ or dialysis); * Severe liver disease (Child-Pugh B/C); * Active malignancy (life expectancy \<1 year); * Severe hematologic disorders (thrombocytopenia, coagulopathy, active bleeding). 3. Fibrinolysis-followed-by-PCI. 4. Primary PCI complications: * No-reflow/slow-flow (final TIMI \<2); * Cardiogenic shock or mechanical complication within 7 days; * In-hospital repeat revascularization. 5. Inability to complete 6-month follow-up. 6. Factors affecting blood sampling/exosome/immune/proteome assays: * Blood transfusion within 1 month; * Known hemolytic disorder; * Inadequate venous access. 7. Pregnancy or lactation.
๐Ÿ’Š

What it tests

  • Diagnostic Test: echocardiography and blood collection
๐Ÿ“

Where

1 site
Beijing Anzhen Hospital, Capital Medical University.
Beijing, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy